u266 cells Search Results


93
Elabscience Biotechnology u266 cells
U266 Cells, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/U266+%5BU266B1%5D+Cell+Complete+Medium/pm40128181-412-8-18
Average 93 stars, based on 1 article reviews
u266 cells - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology u266 cells
U266 Cells, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/U266+Whole+Cell+Lysate/pm28721629-56-7-21
Average 93 stars, based on 1 article reviews
u266 cells - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Jackson Laboratory luciferase-labeled u266 cells
Specificity and antibody-binding capacity of DKK1-A2 mAb. (A) The binding of DKK1-A2 mAbs to different molecules or immune complexes coated on the plate was measured by ELISA. (B) Surface binding ability of DKK1-A2 (C2, HMB1, or HMB7) mAbs to MM cell lines <t>U266</t> (HLA-A2 + ) and ARP-1 (HLA-A2 – ). Confocal immunofluorescent microscopy images showing (C) U266, Granta 519, and ARP-1 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 647 (A647)-conjugated DKK1 mAb (red), and DAPI (blue). Merged images are depicted on the right; and (D) T2 cells, T2 cells loaded with P20, T2 cells loaded with P66v, U266, or Granta 519 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 594 (A594)-conjugated HLA-A2 mAb (red), and DAPI (blue). Merged images are depicted on the right. (E) Surface binding affinity of C2 mAb at indicated concentrations to U266 cells. (F) T2 cells were loaded with different concentrations of DKK1 P20 or P66v peptide overnight and analyzed for binding affinity (MFI) of C2 mAb to the surface DKK1-A2 complex. (G) The binding capacity of C2 mAb to normal PBMC and plasma cells from MGUS or patients with MM, and U266, and (H) Summary of results. (I) The surface expression of HLA-A2 and DKK1-A2 complex (stained by C2 mAb), and intracellular expression of DKK1 protein in primary MM cells from eight patients (Pt01–Pt08) was measured by flow cytometry. Error bars=SD.***p<0.001; ****p<0.0001. DAPI, 4’, 6-diamidino-2-phenylindole, dihydrochloride; DKK1, Dickkopf-1; mAb, monoclonal antibodies; MFI, mean fluorescent intensity; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PBMC, peripheral blood mononuclear cell.
Luciferase Labeled U266 Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/u266+cells/pmc10824003-113-10-20
Average 90 stars, based on 1 article reviews
luciferase-labeled u266 cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
iCell Bioscience Inc u266
Specificity and antibody-binding capacity of DKK1-A2 mAb. (A) The binding of DKK1-A2 mAbs to different molecules or immune complexes coated on the plate was measured by ELISA. (B) Surface binding ability of DKK1-A2 (C2, HMB1, or HMB7) mAbs to MM cell lines <t>U266</t> (HLA-A2 + ) and ARP-1 (HLA-A2 – ). Confocal immunofluorescent microscopy images showing (C) U266, Granta 519, and ARP-1 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 647 (A647)-conjugated DKK1 mAb (red), and DAPI (blue). Merged images are depicted on the right; and (D) T2 cells, T2 cells loaded with P20, T2 cells loaded with P66v, U266, or Granta 519 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 594 (A594)-conjugated HLA-A2 mAb (red), and DAPI (blue). Merged images are depicted on the right. (E) Surface binding affinity of C2 mAb at indicated concentrations to U266 cells. (F) T2 cells were loaded with different concentrations of DKK1 P20 or P66v peptide overnight and analyzed for binding affinity (MFI) of C2 mAb to the surface DKK1-A2 complex. (G) The binding capacity of C2 mAb to normal PBMC and plasma cells from MGUS or patients with MM, and U266, and (H) Summary of results. (I) The surface expression of HLA-A2 and DKK1-A2 complex (stained by C2 mAb), and intracellular expression of DKK1 protein in primary MM cells from eight patients (Pt01–Pt08) was measured by flow cytometry. Error bars=SD.***p<0.001; ****p<0.0001. DAPI, 4’, 6-diamidino-2-phenylindole, dihydrochloride; DKK1, Dickkopf-1; mAb, monoclonal antibodies; MFI, mean fluorescent intensity; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PBMC, peripheral blood mononuclear cell.
U266, supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/cell+lines+u266/pm40035958-37-3-14
Average 90 stars, based on 1 article reviews
u266 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
iCell Gene Therapeutics human cell line u266 icell-h266
Specificity and antibody-binding capacity of DKK1-A2 mAb. (A) The binding of DKK1-A2 mAbs to different molecules or immune complexes coated on the plate was measured by ELISA. (B) Surface binding ability of DKK1-A2 (C2, HMB1, or HMB7) mAbs to MM cell lines <t>U266</t> (HLA-A2 + ) and ARP-1 (HLA-A2 – ). Confocal immunofluorescent microscopy images showing (C) U266, Granta 519, and ARP-1 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 647 (A647)-conjugated DKK1 mAb (red), and DAPI (blue). Merged images are depicted on the right; and (D) T2 cells, T2 cells loaded with P20, T2 cells loaded with P66v, U266, or Granta 519 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 594 (A594)-conjugated HLA-A2 mAb (red), and DAPI (blue). Merged images are depicted on the right. (E) Surface binding affinity of C2 mAb at indicated concentrations to U266 cells. (F) T2 cells were loaded with different concentrations of DKK1 P20 or P66v peptide overnight and analyzed for binding affinity (MFI) of C2 mAb to the surface DKK1-A2 complex. (G) The binding capacity of C2 mAb to normal PBMC and plasma cells from MGUS or patients with MM, and U266, and (H) Summary of results. (I) The surface expression of HLA-A2 and DKK1-A2 complex (stained by C2 mAb), and intracellular expression of DKK1 protein in primary MM cells from eight patients (Pt01–Pt08) was measured by flow cytometry. Error bars=SD.***p<0.001; ****p<0.0001. DAPI, 4’, 6-diamidino-2-phenylindole, dihydrochloride; DKK1, Dickkopf-1; mAb, monoclonal antibodies; MFI, mean fluorescent intensity; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PBMC, peripheral blood mononuclear cell.
Human Cell Line U266 Icell H266, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/human+cell+line+u266+icell+h266/pmc11162407-67-1-6
Average 90 stars, based on 1 article reviews
human cell line u266 icell-h266 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
European Collection of Authenticated Cell Cultures human myeloma u266
In vitro cell viability results post‐treatment on PANC‐1 and <t> U266 </t> cell lines after 72 h. Data represented as the mean±SD; n=3. The levels of significance are shown as follows: x: P <0.05 ; y: P <0.01 ; z: P <0.001 , determined by the One‐wayANOVA test followed by Fishers LSD post hoc test.
Human Myeloma U266, supplied by European Collection of Authenticated Cell Cultures, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/human+myeloma+u266/pmc11979682-193-7-20
Average 90 stars, based on 1 article reviews
human myeloma u266 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Becton Dickinson target cell line u266
In vitro cell viability results post‐treatment on PANC‐1 and <t> U266 </t> cell lines after 72 h. Data represented as the mean±SD; n=3. The levels of significance are shown as follows: x: P <0.05 ; y: P <0.01 ; z: P <0.001 , determined by the One‐wayANOVA test followed by Fishers LSD post hoc test.
Target Cell Line U266, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/target+cell+line+u266/pm38641734-319-1-17
Average 90 stars, based on 1 article reviews
target cell line u266 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Korean Cell Line Bank u266 cell line
Metabolic screen of multiple myeloma cells. ( A ) Schematic for metabolic screening targeting glycolysis pathway in MM cells. ( B ) Assay for metabolic efficiency of compounds from NCI-drug library on RPMI8226 and U266 MM cells; <t>HEK293</t> cells were used to determine the toxicity of the compounds. Each point represents a single compound from the library; the assay was performed in duplicate for reproducibility (Vo = vorinostat, Vi = vismodegib, Pa = palbociclib, Po = ponatinib, Bi = binimetinib). Cells were incubated with the drug compounds for 72 h for the assay. ( C ) Schematic diagram of the glycolysis pathway for the enzymatic links. ( D , E ) The top ten selected drug candidates were screened for inhibition of glycolytic genes by qPCR. The drug treatment was for 12 h on RPMI8226 cells. ( F ) The top 5 candidates were further screened for inhibition in lactate production using a lactate assay kit on RPMI8226 cells; drug treatment was for 24 h. Data are presented as mean ± SEM; t -test: *** p < 0.001. ( G ) Venn diagram shows ponatinib was the best candidate compound for glycolysis gene and lactate production inhibition. ( H ) HK2 and GPI signals were analyzed in normal and MM cells in cancer patients. The patient data were obtained from the R2 platform (hgserver1.amc.nl) (GEO ID: GSE2658). N = normal tissue; T = tumor. Data are plotted as mean with the shaded distributions; * p < 0.05, *** p < 0.001, provided by R2 platform search engine (via one-way ANOVA on ranks). ( I ) Kaplan–Meier overall survival plots of MM patients with respect to HK2 and GPI RNA message levels are shown. Significance p-values are indicated in the figure, provided by R2 platform search engine (hgserver1.amc.nl) (GEO ID: GSE2658) (via one-way ANOVA on ranks).
U266 Cell Line, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/u266+cell+line/pmc09179535-38-5-15
Average 90 stars, based on 1 article reviews
u266 cell line - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
China Center for Type Culture Collection cell line u266
Metabolic screen of multiple myeloma cells. ( A ) Schematic for metabolic screening targeting glycolysis pathway in MM cells. ( B ) Assay for metabolic efficiency of compounds from NCI-drug library on RPMI8226 and U266 MM cells; <t>HEK293</t> cells were used to determine the toxicity of the compounds. Each point represents a single compound from the library; the assay was performed in duplicate for reproducibility (Vo = vorinostat, Vi = vismodegib, Pa = palbociclib, Po = ponatinib, Bi = binimetinib). Cells were incubated with the drug compounds for 72 h for the assay. ( C ) Schematic diagram of the glycolysis pathway for the enzymatic links. ( D , E ) The top ten selected drug candidates were screened for inhibition of glycolytic genes by qPCR. The drug treatment was for 12 h on RPMI8226 cells. ( F ) The top 5 candidates were further screened for inhibition in lactate production using a lactate assay kit on RPMI8226 cells; drug treatment was for 24 h. Data are presented as mean ± SEM; t -test: *** p < 0.001. ( G ) Venn diagram shows ponatinib was the best candidate compound for glycolysis gene and lactate production inhibition. ( H ) HK2 and GPI signals were analyzed in normal and MM cells in cancer patients. The patient data were obtained from the R2 platform (hgserver1.amc.nl) (GEO ID: GSE2658). N = normal tissue; T = tumor. Data are plotted as mean with the shaded distributions; * p < 0.05, *** p < 0.001, provided by R2 platform search engine (via one-way ANOVA on ranks). ( I ) Kaplan–Meier overall survival plots of MM patients with respect to HK2 and GPI RNA message levels are shown. Significance p-values are indicated in the figure, provided by R2 platform search engine (hgserver1.amc.nl) (GEO ID: GSE2658) (via one-way ANOVA on ranks).
Cell Line U266, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/cells+u266/pmc07294933-29-0-11
Average 90 stars, based on 1 article reviews
cell line u266 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Hayashibara Biochemical Laboratories u266 cell line
Metabolic screen of multiple myeloma cells. ( A ) Schematic for metabolic screening targeting glycolysis pathway in MM cells. ( B ) Assay for metabolic efficiency of compounds from NCI-drug library on RPMI8226 and U266 MM cells; <t>HEK293</t> cells were used to determine the toxicity of the compounds. Each point represents a single compound from the library; the assay was performed in duplicate for reproducibility (Vo = vorinostat, Vi = vismodegib, Pa = palbociclib, Po = ponatinib, Bi = binimetinib). Cells were incubated with the drug compounds for 72 h for the assay. ( C ) Schematic diagram of the glycolysis pathway for the enzymatic links. ( D , E ) The top ten selected drug candidates were screened for inhibition of glycolytic genes by qPCR. The drug treatment was for 12 h on RPMI8226 cells. ( F ) The top 5 candidates were further screened for inhibition in lactate production using a lactate assay kit on RPMI8226 cells; drug treatment was for 24 h. Data are presented as mean ± SEM; t -test: *** p < 0.001. ( G ) Venn diagram shows ponatinib was the best candidate compound for glycolysis gene and lactate production inhibition. ( H ) HK2 and GPI signals were analyzed in normal and MM cells in cancer patients. The patient data were obtained from the R2 platform (hgserver1.amc.nl) (GEO ID: GSE2658). N = normal tissue; T = tumor. Data are plotted as mean with the shaded distributions; * p < 0.05, *** p < 0.001, provided by R2 platform search engine (via one-way ANOVA on ranks). ( I ) Kaplan–Meier overall survival plots of MM patients with respect to HK2 and GPI RNA message levels are shown. Significance p-values are indicated in the figure, provided by R2 platform search engine (hgserver1.amc.nl) (GEO ID: GSE2658) (via one-way ANOVA on ranks).
U266 Cell Line, supplied by Hayashibara Biochemical Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/u266+cell+line/pm18480596-37-0-6
Average 90 stars, based on 1 article reviews
u266 cell line - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
JCRB Cell Bank cell lines u266 pir
Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on <t>U266</t> PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).
Cell Lines U266 Pir, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/cell+lines+u266+pir/pmc10137151-76-7-20
Average 90 stars, based on 1 article reviews
cell lines u266 pir - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Charite Research Organisation u266 human cell line
Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on <t>U266</t> PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).
U266 Human Cell Line, supplied by Charite Research Organisation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u266+cells/u266+human+cell+line/pm37190302-41-3-14
Average 90 stars, based on 1 article reviews
u266 human cell line - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Specificity and antibody-binding capacity of DKK1-A2 mAb. (A) The binding of DKK1-A2 mAbs to different molecules or immune complexes coated on the plate was measured by ELISA. (B) Surface binding ability of DKK1-A2 (C2, HMB1, or HMB7) mAbs to MM cell lines U266 (HLA-A2 + ) and ARP-1 (HLA-A2 – ). Confocal immunofluorescent microscopy images showing (C) U266, Granta 519, and ARP-1 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 647 (A647)-conjugated DKK1 mAb (red), and DAPI (blue). Merged images are depicted on the right; and (D) T2 cells, T2 cells loaded with P20, T2 cells loaded with P66v, U266, or Granta 519 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 594 (A594)-conjugated HLA-A2 mAb (red), and DAPI (blue). Merged images are depicted on the right. (E) Surface binding affinity of C2 mAb at indicated concentrations to U266 cells. (F) T2 cells were loaded with different concentrations of DKK1 P20 or P66v peptide overnight and analyzed for binding affinity (MFI) of C2 mAb to the surface DKK1-A2 complex. (G) The binding capacity of C2 mAb to normal PBMC and plasma cells from MGUS or patients with MM, and U266, and (H) Summary of results. (I) The surface expression of HLA-A2 and DKK1-A2 complex (stained by C2 mAb), and intracellular expression of DKK1 protein in primary MM cells from eight patients (Pt01–Pt08) was measured by flow cytometry. Error bars=SD.***p<0.001; ****p<0.0001. DAPI, 4’, 6-diamidino-2-phenylindole, dihydrochloride; DKK1, Dickkopf-1; mAb, monoclonal antibodies; MFI, mean fluorescent intensity; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PBMC, peripheral blood mononuclear cell.

Journal: Journal for Immunotherapy of Cancer

Article Title: Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers

doi: 10.1136/jitc-2023-008145

Figure Lengend Snippet: Specificity and antibody-binding capacity of DKK1-A2 mAb. (A) The binding of DKK1-A2 mAbs to different molecules or immune complexes coated on the plate was measured by ELISA. (B) Surface binding ability of DKK1-A2 (C2, HMB1, or HMB7) mAbs to MM cell lines U266 (HLA-A2 + ) and ARP-1 (HLA-A2 – ). Confocal immunofluorescent microscopy images showing (C) U266, Granta 519, and ARP-1 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 647 (A647)-conjugated DKK1 mAb (red), and DAPI (blue). Merged images are depicted on the right; and (D) T2 cells, T2 cells loaded with P20, T2 cells loaded with P66v, U266, or Granta 519 cells costained with Alexa Fluor 488 (A488)-conjugated C2 mAb (green), Alexa Fluor 594 (A594)-conjugated HLA-A2 mAb (red), and DAPI (blue). Merged images are depicted on the right. (E) Surface binding affinity of C2 mAb at indicated concentrations to U266 cells. (F) T2 cells were loaded with different concentrations of DKK1 P20 or P66v peptide overnight and analyzed for binding affinity (MFI) of C2 mAb to the surface DKK1-A2 complex. (G) The binding capacity of C2 mAb to normal PBMC and plasma cells from MGUS or patients with MM, and U266, and (H) Summary of results. (I) The surface expression of HLA-A2 and DKK1-A2 complex (stained by C2 mAb), and intracellular expression of DKK1 protein in primary MM cells from eight patients (Pt01–Pt08) was measured by flow cytometry. Error bars=SD.***p<0.001; ****p<0.0001. DAPI, 4’, 6-diamidino-2-phenylindole, dihydrochloride; DKK1, Dickkopf-1; mAb, monoclonal antibodies; MFI, mean fluorescent intensity; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PBMC, peripheral blood mononuclear cell.

Article Snippet: To generate human MM xenograft mouse model, 1×10 6 luciferase-labeled U266 cells were intravenously inoculated into 6-week-old female SCID mice (The Jackson Laboratory, Bar Harbor, Maine, USA).

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Microscopy, Expressing, Staining, Flow Cytometry

DKK1-A2 mAbs at high concentrations induce apoptosis in cancer cells in vitro. (A) Apoptosis of U266 cells induced by C2 mAb at different concentrations. Mouse IgG1 (mIgG1) served as control. (B) T2 cells were loaded with different concentrations of DKK1 P20 peptide overnight and then washed and treated with 50 μg/mL C2 mAb or mIgG1 for 48 hours, followed by analysis for apoptosis. (C) Apoptosis of T2 cells loaded without or with different peptides and then treated with 50 µg/mL DKK1-A2 C2, HMB1 or HMB7 mAb or mIgG1. (D) Apoptosis of MM cell lines U266, DKK1-knockdown U266 (U266-DKK1-KD), and ARP-1, lymphoma cell lines Granta 519, leukemia cell line ARH-77, primary MM cells from two patients (Pt05 and Pt06), and normal B cells in 48-hour culture with 50 µg/mL C2 mAb or mIgG1. (E) The expression of total and cleaved caspases, PARP, and cytochrome c (Cyto c), Bax, and phosphorylated (P) Bcl2 and Bad in U266 and Granta 519 cells treated with 50 µg/mL C2 mAb for different times measured by western blot. Error bars=SD. *p<0.05; **p<0.01. DKK1, Dickkopf-1; mAb, monoclonal antibodies; MM, multiple myeloma; PARP, poly(ADP-ribose) polymerase; pBad, phosphorylated Bad; pBcl2, phosphorylated Bcl-2.

Journal: Journal for Immunotherapy of Cancer

Article Title: Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers

doi: 10.1136/jitc-2023-008145

Figure Lengend Snippet: DKK1-A2 mAbs at high concentrations induce apoptosis in cancer cells in vitro. (A) Apoptosis of U266 cells induced by C2 mAb at different concentrations. Mouse IgG1 (mIgG1) served as control. (B) T2 cells were loaded with different concentrations of DKK1 P20 peptide overnight and then washed and treated with 50 μg/mL C2 mAb or mIgG1 for 48 hours, followed by analysis for apoptosis. (C) Apoptosis of T2 cells loaded without or with different peptides and then treated with 50 µg/mL DKK1-A2 C2, HMB1 or HMB7 mAb or mIgG1. (D) Apoptosis of MM cell lines U266, DKK1-knockdown U266 (U266-DKK1-KD), and ARP-1, lymphoma cell lines Granta 519, leukemia cell line ARH-77, primary MM cells from two patients (Pt05 and Pt06), and normal B cells in 48-hour culture with 50 µg/mL C2 mAb or mIgG1. (E) The expression of total and cleaved caspases, PARP, and cytochrome c (Cyto c), Bax, and phosphorylated (P) Bcl2 and Bad in U266 and Granta 519 cells treated with 50 µg/mL C2 mAb for different times measured by western blot. Error bars=SD. *p<0.05; **p<0.01. DKK1, Dickkopf-1; mAb, monoclonal antibodies; MM, multiple myeloma; PARP, poly(ADP-ribose) polymerase; pBad, phosphorylated Bad; pBcl2, phosphorylated Bcl-2.

Article Snippet: To generate human MM xenograft mouse model, 1×10 6 luciferase-labeled U266 cells were intravenously inoculated into 6-week-old female SCID mice (The Jackson Laboratory, Bar Harbor, Maine, USA).

Techniques: In Vitro, Expressing, Western Blot

Dickkopf-1 -A2 mAbs are therapeutic against established tumors in vivo. (A–D) SCID mice were injected intravenously with luciferase-labeled U266 MM cells, followed by treatment with intraperitoneal injections (every 3 days for a total of six injections) of 200 µg C2 mAb or mIgG. PBS served as a control. Tumor burdens were monitored by (A) in vivo imaging, (B) levels of circulating human M-protein or its light chain, and (C) in vivo bioluminescence plus X-ray imaging. Mouse survival is also shown in (B). (D) Three weeks after the treatment, bone marrow cells and splenocytes were collected for analyzing human CD138 + MM cells using flow cytometry. Summary data is shown. (E–F) SCID mice were injected subcutaneously with Granta 519 lymphoma cells, followed by treatment with intraperitoneal injections (every 3 days for a total of six injections) of 200 µg C2 mAb or mIgG. PBS served as a control. Tumor burdens were measured twice every week by (E) IVIS imaging system and (F) tumor sizes measured by caliper. Mouse survival is shown in (F). (G–H) SCID mice were injected subcutaneously with ARH-77 leukemia cells, followed by treatment with intraperitoneal injections (every 3 days for a total of six injections) of 200 µg C2 mAb or mIgG. PBS served as a control. Tumor burdens were measured twice every week by (G) IVIS imaging system and (H) caliper. Mouse survival is shown in (H). Error bars=SD. *p<0.05; **p<0.01. mAb, monoclonal antibodies; mIgG1, mouse IgG1; MM, multiple myeloma; PBS, phosphate-buffered saline.

Journal: Journal for Immunotherapy of Cancer

Article Title: Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers

doi: 10.1136/jitc-2023-008145

Figure Lengend Snippet: Dickkopf-1 -A2 mAbs are therapeutic against established tumors in vivo. (A–D) SCID mice were injected intravenously with luciferase-labeled U266 MM cells, followed by treatment with intraperitoneal injections (every 3 days for a total of six injections) of 200 µg C2 mAb or mIgG. PBS served as a control. Tumor burdens were monitored by (A) in vivo imaging, (B) levels of circulating human M-protein or its light chain, and (C) in vivo bioluminescence plus X-ray imaging. Mouse survival is also shown in (B). (D) Three weeks after the treatment, bone marrow cells and splenocytes were collected for analyzing human CD138 + MM cells using flow cytometry. Summary data is shown. (E–F) SCID mice were injected subcutaneously with Granta 519 lymphoma cells, followed by treatment with intraperitoneal injections (every 3 days for a total of six injections) of 200 µg C2 mAb or mIgG. PBS served as a control. Tumor burdens were measured twice every week by (E) IVIS imaging system and (F) tumor sizes measured by caliper. Mouse survival is shown in (F). (G–H) SCID mice were injected subcutaneously with ARH-77 leukemia cells, followed by treatment with intraperitoneal injections (every 3 days for a total of six injections) of 200 µg C2 mAb or mIgG. PBS served as a control. Tumor burdens were measured twice every week by (G) IVIS imaging system and (H) caliper. Mouse survival is shown in (H). Error bars=SD. *p<0.05; **p<0.01. mAb, monoclonal antibodies; mIgG1, mouse IgG1; MM, multiple myeloma; PBS, phosphate-buffered saline.

Article Snippet: To generate human MM xenograft mouse model, 1×10 6 luciferase-labeled U266 cells were intravenously inoculated into 6-week-old female SCID mice (The Jackson Laboratory, Bar Harbor, Maine, USA).

Techniques: In Vivo, Injection, Luciferase, Labeling, In Vivo Imaging, Imaging, Flow Cytometry, Saline

In vivo therapeutic effects of Dickkopf-1-A2 mAbs depend on NK cells and are enhanced by lenalidomide. (A–C) SCID mice were xenografted subcutaneously with U266 MM cells followed by treatment with 200 µg mIgG1 or C2 mAb, C2 mAb combined with NK cell depletion by injection of 100 µg specific antibodies (NK depletion), or C2 mAb combined with complement depletion by injection of cobra venom factor (CVF; CP depletion). Tumor burdens were measured twice every week by (A) IVIS imaging system and (B) caliper. Mouse survival is shown in (C). (D–F) SCID mice were challenged subcutaneously with U266 MM cells, followed by treatment with intraperitoneal injections of 200 µg C2 mAb or mIgG1 (every 3 days for a total of six injections), lenalidomide (10 mg/kg, for 5 days and 2 days off for 3 weeks) or lenalidomide plus C2 mAb. Tumor burdens were measured twice every week by (D) IVIS imaging system and (E) caliper. Mouse survival is shown in (F). Representative results of one out of two independent experiments performed are shown. Error bars=SD. *p<0.05, compared with mIgG1 control. mAb, monoclonal antibodies; mIgG1, mouse; NK, natural killer.

Journal: Journal for Immunotherapy of Cancer

Article Title: Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers

doi: 10.1136/jitc-2023-008145

Figure Lengend Snippet: In vivo therapeutic effects of Dickkopf-1-A2 mAbs depend on NK cells and are enhanced by lenalidomide. (A–C) SCID mice were xenografted subcutaneously with U266 MM cells followed by treatment with 200 µg mIgG1 or C2 mAb, C2 mAb combined with NK cell depletion by injection of 100 µg specific antibodies (NK depletion), or C2 mAb combined with complement depletion by injection of cobra venom factor (CVF; CP depletion). Tumor burdens were measured twice every week by (A) IVIS imaging system and (B) caliper. Mouse survival is shown in (C). (D–F) SCID mice were challenged subcutaneously with U266 MM cells, followed by treatment with intraperitoneal injections of 200 µg C2 mAb or mIgG1 (every 3 days for a total of six injections), lenalidomide (10 mg/kg, for 5 days and 2 days off for 3 weeks) or lenalidomide plus C2 mAb. Tumor burdens were measured twice every week by (D) IVIS imaging system and (E) caliper. Mouse survival is shown in (F). Representative results of one out of two independent experiments performed are shown. Error bars=SD. *p<0.05, compared with mIgG1 control. mAb, monoclonal antibodies; mIgG1, mouse; NK, natural killer.

Article Snippet: To generate human MM xenograft mouse model, 1×10 6 luciferase-labeled U266 cells were intravenously inoculated into 6-week-old female SCID mice (The Jackson Laboratory, Bar Harbor, Maine, USA).

Techniques: In Vivo, Injection, Combined Bisulfite Restriction Analysis Assay, Imaging

Evaluation of in vivo toxicity and safety of DKK1-A2 mAbs. (A) DKK1 mRNA expression profile in human solid tumors compared with their normal tissues or organs based on data in the Oncomine database. (B) DKK1 mRNA expression profile in leukemias compared with normal human PBMC based on GSE13159 in the Oncomine database. (C) DKK1 mRNA expression in lymphomas compared with normal human blood B cells (BL) based on GSE12195 in the Oncomine database. (D) DKK1 mRNA expression profile in MM, MGUS, and plasma cell leukemia (PCL) compared with normal human BM plasma cells (PC) based on GSE13591 in the Oncomine database. A2-SCID mice were inoculated subcutaneously with U266 MM cells, followed by treatment with intraperitoneal injections (every 3 days for a total of six injections) of 400 µg C2 mAb or mIgG1. On day 3 after the final injection, mice were sacrificed, and tumor and normal tissues were harvested for the following examinations; (E, upper panel) H&E staining, (E, lower panel) detection of the DKK1-A2 complex by C2 mAb staining, (F) mean fluorescent intensity (MFI) showing the expression level of HLA-A2 and DKK1-A2 complex (detected by C2 mAb) on different tissues and tumors, and (G and H) detection of apoptotic cells by TUNEL assay. (I) The surface expression of HLA-A2 and DKK1-A2 complex (stained by C2 mAb) in normal human bone marrow, breast, lung and pancreas was measured by flow cytometry. (J) Normal HLA-A2 positive human breast (n=5), lung (n=5) and pancreas (n=5) were stained by IHC staining with C2 antibody. Representative results of one out of two independent experiments are shown. Error bars=SD. **p<0.01 (compared with controls). ACC, adrenocortical carcinoma; AML, acute myeloid leukemia; BALL, B-cell acute lymphoblastic leukemia; BC, breast cancer; BCALL, B-cell childhood acute lymphoblastic leukemia; BL, B-lymphocyte; BLCA, bladder urothelial carcinoma; BM, bone marrow; BRCA, breast invasive carcinoma; CC, cervical cancer; CLL, chronic lymphocyte leukemia; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; CML, chronic myelomonocyte leukemia; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; DKK1A, Dickkopf-1; ESCA, esophageal carcinoma; FHC, fibrous histiocytoma; FL, follicular lymphoma; FSA, fibrosarcoma; GBM, glioblastoma multiforme; HCCA, hepatocellular carcinoma; HD, health donor; HL, Hodgkin’s lymphoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LCLC, large cell lung carcinoma; LPSA, liposarcoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; mAb, monoclonal antibodies; MCL, mantle cell lymphoma; mIgG1, mouse IgG1; MFSA, myxofibrosarcoma; MGCT, mixed germ cell tumor; MGUS, monoclonal gammopathy of undetermined significance, MLNA, melanoma; MM, multiple myeloma; mRNA, messenger RNA; MS, myelodysplastic syndrome; OV, ovarian serous cystadenocarcinoma; PBALL, pro-B acute lymphoblastic leukemia; PC, plasma cells; PCA, pancreatic carcinoma; PCL, plasma cell leukemia; PCPG, pheochromocytoma and paraganglioma; PDAC, pancreatic ductal adenocarcinoma, PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; RCC, renal cell carcinoma; SARC, sarcoma; SCLC, squamous cell lung carcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TALL, T-cell acute lymphoblastic leukemia; TCL, T-cell lymphoma; TCPL, T-cell prolymphocytic leukemia; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; TT, testicular teratoma, TYST, testicular yolk sac tumor; UCEC, uterine corpus endometrial carcinoma, UCS, uterine carcinosarcoma; YST, yolk sac tumor. IHC, Immunohistochemistry; MCI, Metadata Coverage Index

Journal: Journal for Immunotherapy of Cancer

Article Title: Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers

doi: 10.1136/jitc-2023-008145

Figure Lengend Snippet: Evaluation of in vivo toxicity and safety of DKK1-A2 mAbs. (A) DKK1 mRNA expression profile in human solid tumors compared with their normal tissues or organs based on data in the Oncomine database. (B) DKK1 mRNA expression profile in leukemias compared with normal human PBMC based on GSE13159 in the Oncomine database. (C) DKK1 mRNA expression in lymphomas compared with normal human blood B cells (BL) based on GSE12195 in the Oncomine database. (D) DKK1 mRNA expression profile in MM, MGUS, and plasma cell leukemia (PCL) compared with normal human BM plasma cells (PC) based on GSE13591 in the Oncomine database. A2-SCID mice were inoculated subcutaneously with U266 MM cells, followed by treatment with intraperitoneal injections (every 3 days for a total of six injections) of 400 µg C2 mAb or mIgG1. On day 3 after the final injection, mice were sacrificed, and tumor and normal tissues were harvested for the following examinations; (E, upper panel) H&E staining, (E, lower panel) detection of the DKK1-A2 complex by C2 mAb staining, (F) mean fluorescent intensity (MFI) showing the expression level of HLA-A2 and DKK1-A2 complex (detected by C2 mAb) on different tissues and tumors, and (G and H) detection of apoptotic cells by TUNEL assay. (I) The surface expression of HLA-A2 and DKK1-A2 complex (stained by C2 mAb) in normal human bone marrow, breast, lung and pancreas was measured by flow cytometry. (J) Normal HLA-A2 positive human breast (n=5), lung (n=5) and pancreas (n=5) were stained by IHC staining with C2 antibody. Representative results of one out of two independent experiments are shown. Error bars=SD. **p<0.01 (compared with controls). ACC, adrenocortical carcinoma; AML, acute myeloid leukemia; BALL, B-cell acute lymphoblastic leukemia; BC, breast cancer; BCALL, B-cell childhood acute lymphoblastic leukemia; BL, B-lymphocyte; BLCA, bladder urothelial carcinoma; BM, bone marrow; BRCA, breast invasive carcinoma; CC, cervical cancer; CLL, chronic lymphocyte leukemia; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; CML, chronic myelomonocyte leukemia; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; DKK1A, Dickkopf-1; ESCA, esophageal carcinoma; FHC, fibrous histiocytoma; FL, follicular lymphoma; FSA, fibrosarcoma; GBM, glioblastoma multiforme; HCCA, hepatocellular carcinoma; HD, health donor; HL, Hodgkin’s lymphoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LCLC, large cell lung carcinoma; LPSA, liposarcoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; mAb, monoclonal antibodies; MCL, mantle cell lymphoma; mIgG1, mouse IgG1; MFSA, myxofibrosarcoma; MGCT, mixed germ cell tumor; MGUS, monoclonal gammopathy of undetermined significance, MLNA, melanoma; MM, multiple myeloma; mRNA, messenger RNA; MS, myelodysplastic syndrome; OV, ovarian serous cystadenocarcinoma; PBALL, pro-B acute lymphoblastic leukemia; PC, plasma cells; PCA, pancreatic carcinoma; PCL, plasma cell leukemia; PCPG, pheochromocytoma and paraganglioma; PDAC, pancreatic ductal adenocarcinoma, PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; RCC, renal cell carcinoma; SARC, sarcoma; SCLC, squamous cell lung carcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TALL, T-cell acute lymphoblastic leukemia; TCL, T-cell lymphoma; TCPL, T-cell prolymphocytic leukemia; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; TT, testicular teratoma, TYST, testicular yolk sac tumor; UCEC, uterine corpus endometrial carcinoma, UCS, uterine carcinosarcoma; YST, yolk sac tumor. IHC, Immunohistochemistry; MCI, Metadata Coverage Index

Article Snippet: To generate human MM xenograft mouse model, 1×10 6 luciferase-labeled U266 cells were intravenously inoculated into 6-week-old female SCID mice (The Jackson Laboratory, Bar Harbor, Maine, USA).

Techniques: In Vivo, Expressing, Injection, Staining, TUNEL Assay, Flow Cytometry, Immunohistochemistry

In vitro cell viability results post‐treatment on PANC‐1 and  U266  cell lines after 72 h. Data represented as the mean±SD; n=3. The levels of significance are shown as follows: x: P <0.05 ; y: P <0.01 ; z: P <0.001 , determined by the One‐wayANOVA test followed by Fishers LSD post hoc test.

Journal: Chemistry (Weinheim an Der Bergstrasse, Germany)

Article Title: New Cytotoxic Derivatives by the Phosphorylation and Phosphinoylation of Diethyl α‐Amino‐α‐Aryl‐Methylphosphonates

doi: 10.1002/chem.202500370

Figure Lengend Snippet: In vitro cell viability results post‐treatment on PANC‐1 and U266 cell lines after 72 h. Data represented as the mean±SD; n=3. The levels of significance are shown as follows: x: P <0.05 ; y: P <0.01 ; z: P <0.001 , determined by the One‐wayANOVA test followed by Fishers LSD post hoc test.

Article Snippet: The two investigated cell lines were a human myeloma (U266) and a human pancreatic ductal adenocarcinoma (PANC‐1) purchased from the European Collection of Authenticated Cell Cultures (ECACC, Salisbury, UK).

Techniques: In Vitro, Concentration Assay

Metabolic screen of multiple myeloma cells. ( A ) Schematic for metabolic screening targeting glycolysis pathway in MM cells. ( B ) Assay for metabolic efficiency of compounds from NCI-drug library on RPMI8226 and U266 MM cells; HEK293 cells were used to determine the toxicity of the compounds. Each point represents a single compound from the library; the assay was performed in duplicate for reproducibility (Vo = vorinostat, Vi = vismodegib, Pa = palbociclib, Po = ponatinib, Bi = binimetinib). Cells were incubated with the drug compounds for 72 h for the assay. ( C ) Schematic diagram of the glycolysis pathway for the enzymatic links. ( D , E ) The top ten selected drug candidates were screened for inhibition of glycolytic genes by qPCR. The drug treatment was for 12 h on RPMI8226 cells. ( F ) The top 5 candidates were further screened for inhibition in lactate production using a lactate assay kit on RPMI8226 cells; drug treatment was for 24 h. Data are presented as mean ± SEM; t -test: *** p < 0.001. ( G ) Venn diagram shows ponatinib was the best candidate compound for glycolysis gene and lactate production inhibition. ( H ) HK2 and GPI signals were analyzed in normal and MM cells in cancer patients. The patient data were obtained from the R2 platform (hgserver1.amc.nl) (GEO ID: GSE2658). N = normal tissue; T = tumor. Data are plotted as mean with the shaded distributions; * p < 0.05, *** p < 0.001, provided by R2 platform search engine (via one-way ANOVA on ranks). ( I ) Kaplan–Meier overall survival plots of MM patients with respect to HK2 and GPI RNA message levels are shown. Significance p-values are indicated in the figure, provided by R2 platform search engine (hgserver1.amc.nl) (GEO ID: GSE2658) (via one-way ANOVA on ranks).

Journal: Cancers

Article Title: mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma

doi: 10.3390/cancers14112766

Figure Lengend Snippet: Metabolic screen of multiple myeloma cells. ( A ) Schematic for metabolic screening targeting glycolysis pathway in MM cells. ( B ) Assay for metabolic efficiency of compounds from NCI-drug library on RPMI8226 and U266 MM cells; HEK293 cells were used to determine the toxicity of the compounds. Each point represents a single compound from the library; the assay was performed in duplicate for reproducibility (Vo = vorinostat, Vi = vismodegib, Pa = palbociclib, Po = ponatinib, Bi = binimetinib). Cells were incubated with the drug compounds for 72 h for the assay. ( C ) Schematic diagram of the glycolysis pathway for the enzymatic links. ( D , E ) The top ten selected drug candidates were screened for inhibition of glycolytic genes by qPCR. The drug treatment was for 12 h on RPMI8226 cells. ( F ) The top 5 candidates were further screened for inhibition in lactate production using a lactate assay kit on RPMI8226 cells; drug treatment was for 24 h. Data are presented as mean ± SEM; t -test: *** p < 0.001. ( G ) Venn diagram shows ponatinib was the best candidate compound for glycolysis gene and lactate production inhibition. ( H ) HK2 and GPI signals were analyzed in normal and MM cells in cancer patients. The patient data were obtained from the R2 platform (hgserver1.amc.nl) (GEO ID: GSE2658). N = normal tissue; T = tumor. Data are plotted as mean with the shaded distributions; * p < 0.05, *** p < 0.001, provided by R2 platform search engine (via one-way ANOVA on ranks). ( I ) Kaplan–Meier overall survival plots of MM patients with respect to HK2 and GPI RNA message levels are shown. Significance p-values are indicated in the figure, provided by R2 platform search engine (hgserver1.amc.nl) (GEO ID: GSE2658) (via one-way ANOVA on ranks).

Article Snippet: Human MM (RPMI8226, U266) and HEK293 cell lines were obtained from Korea cell line bank (KCLB) and the American Type Culture Collection (ATCC) (Manassas, VA, USA).

Techniques: Drug discovery, Incubation, Inhibition, Lactate Assay

Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on U266 PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).

Journal: Cancers

Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines

doi: 10.3390/cancers15082199

Figure Lengend Snippet: Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on U266 PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).

Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).

Techniques: Drug discovery, Inhibition

EHMT2 inhibition synergically increases proteasome inhibitor-mediated cell death in PI-resistant and PI-sensitive multiple myeloma cell lines. ( a ) Heatmap representing cell viability after single and combinatorial treatment in U266 PIR -, KMM1 PIR -, AMO1 PIR -, RPMI PIRBTZ -, and RPMI PIRCFZ -resistant cell lines and U266-, KMM-1-, KMS28-BM-, AMO-1-, RPMI-8226-, and OPM-2-sensitive cell lines. Analysis was performed 72 h post-treatment with FACS or the CellTiterGlo assay ( n = 3). ( b – d ) SynergyFinder analysis of UNC0642/CFZ dose–response matrixes. Percentage of inhibition was retrieved with the CellTiter Glo assay 72 h post-treatment and normalized to the luminescent signal measured at day 0. Synergy score was calculated with Bliss.

Journal: Cancers

Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines

doi: 10.3390/cancers15082199

Figure Lengend Snippet: EHMT2 inhibition synergically increases proteasome inhibitor-mediated cell death in PI-resistant and PI-sensitive multiple myeloma cell lines. ( a ) Heatmap representing cell viability after single and combinatorial treatment in U266 PIR -, KMM1 PIR -, AMO1 PIR -, RPMI PIRBTZ -, and RPMI PIRCFZ -resistant cell lines and U266-, KMM-1-, KMS28-BM-, AMO-1-, RPMI-8226-, and OPM-2-sensitive cell lines. Analysis was performed 72 h post-treatment with FACS or the CellTiterGlo assay ( n = 3). ( b – d ) SynergyFinder analysis of UNC0642/CFZ dose–response matrixes. Percentage of inhibition was retrieved with the CellTiter Glo assay 72 h post-treatment and normalized to the luminescent signal measured at day 0. Synergy score was calculated with Bliss.

Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).

Techniques: Inhibition, Glo Assay